Fatigue after initiating rivaroxaban for venous thromboembolism
Abstract Background Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaba...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2020-05-01
|
| Collection: | Research and Practice in Thrombosis and Haemostasis |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1002/rth2.12312 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|